Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF‐TIMI 48 Trial

BACKGROUND: Anticoagulation in patients with malignancy and atrial fibrillation is challenging because of enhanced risks for thrombosis and bleeding and the frequent need for invasive procedures. Data on direct oral antagonists in such patients are sparse. METHODS AND RESULTS: The ENGAGE AF‐TIMI 48...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Am Heart Assoc
Hauptverfasser: Fanola, Christina L., Ruff, Christian T., Murphy, Sabina A., Jin, James, Duggal, Anil, Babilonia, Noe A., Sritara, Piyamitr, Mercuri, Michele F., Kamphuisen, Pieter W., Antman, Elliott M., Braunwald, Eugene, Giugliano, Robert P.
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2018
Schlagworte:
Original Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6201390/
https://ncbi.nlm.nih.gov/pubmed/30369307
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.118.008987
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge